Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

Affiliations

• ¹ Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
• ² Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA.
• ³ Department of Allergy and Clinical Immunology, Cleveland Clinic, Cleveland, Ohio, USA.
• ⁴ Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA calabrl@ccf.org.